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Abstract 
This study used a damaged skin, porcine model to evaluate the in vivo efficacy of 
WoundStat™ for decontamination of superficial (non-haemorrhaging), sulphur 
mustard-contaminated wounds. The dorsal skin of 12 female pigs was subjected to 
controlled physical damage and exposed to 10 µL 14C-radiolabelled sulphur mustard 
(14C-SM). Animals were randomly assigned to either a control or a treatment group. 
In the latter, WoundStat™ was applied 30 s post exposure and left in situ for 1 h. 
Skin lesion progression and decontaminant efficacy were quantified over 6 hours 
using a range of biophysical measurements. Skin, blood and organ samples were 
taken post mortem for histopathological assessment, 14C-SM distribution and 
toxicokinetic analyses. Application of SM to damaged skin without decontamination 
was rapidly followed by advanced signs of toxicity, including ulceration and 
decreased blood flow at the exposure site in all animals. WoundStat™ prevented 
ulceration and improved blood flow at the exposure site in 100% of decontaminated 
animals (n=6). Furthermore, significantly smaller quantities of 14C-SM were detected 
in the blood (45% reduction), and recovered from skin (70% reduction) and skin 
surface swabs (99% reduction) at 6 hours post-challenge. Overall, the distribution of 
14C-SM in the internal organs was similar for both groups, with the greatest 
concentration in the kidneys, followed by the liver and small intestine. WoundStat™ 
significantly reduced the amount of 14C-SM recovered from the liver, a key organ for 
SM metabolism and detoxification. This study demonstrates that WoundStat™ is a 
suitable product for reducing the ingress and toxicity of a chemical warfare agent. 
 
 
Short abstract 
 
Application of 14C-radiolabelled sulphur mustard (14C-SM) to damaged pig skin 
without decontamination resulted in advanced signs of toxicity with rapid onset (n=6). 
Application of WoundStat™ post exposure prevented or delayed signs of toxicity in 
all decontaminated animals (n=6) and improved perfusion at the exposure site, while 
significantly smaller quantities of 14C-SM were detected in the blood and recovered 
from the skin. This study demonstrates that WoundStat™ is suitable for reducing the 
ingress and toxicity of a vesicant agent. 
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Introduction 
Sulphur mustard (SM) is an incapacitating chemical warfare (CW) agent that 
poses a threat to both civilian and military populations (Wattana and Bey 2009). 
Despite extensive research since its first reported use almost 100 years ago in 
Ypres, Belgium (Ireland, 1926) the exact mechanism of SM toxicity remains elusive 
and therapy is limited to symptomatic treatment (Jenner and Graham, 2013; Rice, 
2016, 2003). Dermal injuries following SM exposure are dose-dependent and 
characterised by erythema, blister formation and ulcerations that are slow to heal 
(Vogt et al., 1984; Petrali and Oglesby-Megee, 1997; Kehe and Szinicz, 2005). 
Additionally, there is a dose-dependent, latent period between SM exposure and the 
signs of toxicity for intact (undamaged) skin (Graham et al., 2005), which is attributed 
to cellular processes, including DNA damage or inflammatory-mediated responses 
(Arroyo et al., 2000; Papirmeister et al., 1985). However, there is little information 
regarding dermal sequelae following SM exposure of compromised skin. 
In vitro studies have shown that both the rate and the total amount of SM 
penetration are significantly enhanced through damaged skin (Lydon et al., 2017), 
Thus, it is conceivable that the progression of SM injury could be more rapid if the 
skin were damaged. Whilst a number of in vivo studies have evaluated 
decontamination of SM-exposed undamaged skin (Chilcott et al., 2007; Taysse et 
al., 2011, 2007; Wormser et al., 2002), data on the decontamination of SM-exposed 
damaged skin are limited to visual scoring of gross lesions and changes in leukocyte 
number (Gold et al., 1994). This paucity of data poses a substantial problem in the 
establishment of best practice protocols for decontaminating individuals who have 
abraded skin or have sustained blast or similar injuries. Furthermore, current 
decontamination regimes are contraindicated for intra-wound use and may adversely 
affect wound healing (Gibbs and Pooley, 1994; Walters et al., 2007). Therefore, a 
product suitable for halting bleeding and decontaminating wounds or abraded skin 
would be of significant clinical benefit. Previous studies have demonstrated that 
WoundStat™, a granular haemostat, has comparable efficacy to in-service military 
decontaminants (fuller’s earth and M291) in the decontamination of both undamaged 
and damaged skin (Dalton et al., 2015, Lydon et al., 2017). Additionally, 
WoundStat™ maintains its haemostatic capability in the presence of toxic chemicals, 
including SM, in vitro (Hall et al., 2015). 
The domestic pig is an established model for evaluating SM-induced 
cutaneous lesions in normal skin (Monteiro-Riviere and Inman, 1997; Chilcott et al., 
2007; Graham et al., 2000; Price et al., 2009; Smith et al., 1997), producing 
epidermal microblisters that are comparable with the blistering seen in humans 
(Brown and Rice, 1997; Mitcheltree et al., 1989). However, the effects of removing 
the skin barrier layer (stratum corneum [SC] and epidermis) on SM lesion 
progression are not well characterised. Therefore, this study characterised early 
progression of SM dermal injuries when applied to damaged porcine skin and 
evaluated the decontaminant efficacy of WoundStat™. 
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Materials and Methods 
Chemicals 
The storage and use of CW agents was in full compliance with the Chemical 
Weapons Convention (1993). Sulphur mustard and its radiolabelled (14C) analogue 
were custom synthesised by TNO Defense (Rijswijk, Netherlands). The purity of the 
agents was determined to be 99.2% and >97% for SM (nuclear magnetic resonance 
analysis) and 14C-SM (gas chromatography–mass spectrometry and high-
performance liquid chromatography analysis), respectively. The 14C-SM solution was 
diluted with unlabelled SM to yield a working solution with a nominal activity of 11 
mCi g-1, which was stored for up to 3 months at 4°C. 
Animal model 
The use of animals was in accordance with the Animals (Scientific 
Procedures) Act (1986). Twelve pigs (Sus scrofa, large white strain, females) were 
purchased from a reputable supplier (weight range 15–25 kg, mean weight 19.5 kg) 
and were kept in pairs with access to food and water ad libitum. Animals were 
housed in a temperature (22–24°C) and humidity (45–65%) controlled environment 
under a 12 h/12 h light/dark cycle.  
Animals were sedated (6 mL, Hypnoval®, Roche Products Ltd.) prior to 
induction of anaesthesia using 3.5–5% isoflurane. Following endotracheal tube 
placement, anaesthesia (1.5–2.5% isofluorane) was maintained and the carotid 
artery and the internal jugular vein were surgically cannulated to provide access for 
arterial blood sampling and intravenous administration of anaesthetic. Alfaxan 
(alfaxalone; 10 mg mL-1 Vétoquinol UK Ltd.) was administered at a rate of 1.0–1.2 
mg kg-1 h-1 for the remainder of the study. Adjustments were made to the anaesthetic 
dose throughout the study to ensure that an appropriate level of consciousness was 
maintained. Physiological parameters (pulse oximetry, capnography, core body 
temperature, electrocardiogram, respiratory rate and blood pressure) were monitored 
throughout the study using a Propaq® Encore 204-EL device (Welch Allyn [UK] Ltd.). 
Experimental procedures 
Animals were randomly assigned to either the SM control (SM-exposed no 
decontamination) or decontamination (SM-exposed with WoundStat™ 
decontamination) group at the start of the study (n=6 for each group). The dorsum of 
all animals was close clipped and up to four dosing rings were attached to identify 
treatment sites. Treatment sites were randomly assigned among multiple dorsal 
sites, using a Latin square design, to reduce the influence of anatomical bias. In the 
SM control group, the treatment sites evaluated the effect of skin damage alone 
(damaged site) and skin damage in combination with SM exposure (SM site). A 
treatment site that was neither damaged nor SM-exposed (control site) was included 
as a negative control. Treatment sites for the decontamination group evaluated the 
effect of (i) skin damage alone (damaged site), (ii) skin damage in combination with 
WoundStat™ (WS site), and (iii) skin damage in combination with WoundStat™ and 
SM exposure (WS + SM site). As in the SM control group, a treatment site that was 
neither damaged nor SM-exposed (control site) was included as a negative control. 
For damaged skin treatment sites, a small (~3 cm2) section of skin was 
removed using a dermatome (Humeca Model D42, Eurosurgical Ltd.) to a nominal 
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depth of 100 µm. Any resulting transient, punctuate bleeding was swabbed with 
cotton gauze soaked in saline to remove extraneous material, such as dried blood. 
Baseline biophysical measurements and blood samples were taken following 
a 30 min stabilisation period post surgery and immediately prior to SM exposure. A 
multi-vesicating (10 µL) dose of 14C-SM was applied as a discrete droplet to one 
damaged skin site. In the WoundStat™ decontamination group, 2 g of WoundStat™ 
was applied to the SM-exposure site 30 s later. WoundStat™ was also applied to an 
unexposed damaged skin site to determine whether WoundStat™ would cause 
adverse reactions in vivo. Both SM and WoundStat™ were removed from the 
treatment sites using cotton swabs and surgical gauze after 60 min so that 
biophysical measurements could be made. To aid the recovery of WoundStat™, 1 
mL of sterile water was applied to the haemostat immediately before removal, so that 
it formed a clay-like mass. The cotton swabs, surgical gauze and WoundStat™ were 
retained for radiometric analysis. 
Biophysical measurements 
Biophysical measurements were made pre-exposure (baseline) and at hourly 
intervals from 60 min post-exposure (approximately 1 min after the removal of 
WoundStat™ and/or SM from treatment site) until the study end (6 h post exposure). 
Dermal blood flow was measured using a laser Doppler line scanner (LDLS, Moor 
Instruments) as previously described (Brown et al., 1998). Repeat line scanner 
images were taken in triplicate (200 ms per line). The region of interest (ROI), 
defined as the area within the dosing ring, was exported for further analyses. Skin 
colour changes were assessed using skin reflectance spectroscopy (SRS; CM-
2600d, Konica Minolta). Standard CIELAB colour space values (L*a*b*) were 
obtained as previously described (Chilcott et al., 2000). Skin surface temperature 
was measured using infrared thermography (FLIR SC620; FLIR Systems). 
Thermographs of the treatment sites were obtained in triplicate. The ROI was 
selected and exported (ThermaCAM™ Researcher software; FLIR Systems Ltd.) for 
further analyses. Skin barrier integrity was evaluated as a function of transepidermal 
water loss (TEWL; AquaFlux AF200; Biox Systems) as previously described (Chilcott 
et al., 2000). Where appropriate, all equipment was calibrated before use in 
accordance with the manufacturer’s guidelines. 
Blood and tissue sampling 
Arterial blood samples (2 mL) were acquired for toxicokinetic analysis prior to 
SM exposure, immediately after SM dosing, and at hourly intervals thereafter. 
Samples were stored in 3.2% sodium citrate vials (Teklab Ltd.) at -20°C prior to 
analysis. Animals were euthanised with a lethal dose of Dolethal (Vétoquinol UK 
Ltd.) at 6 h post-exposure. The skin from each treatment site was excised and 
representative samples were taken for histological and radiometric analysis. Post 
mortem examinations were performed, during which the main organs (brain, heart, 
lung, liver, kidney, pancreas and spleen) were removed and weighed, and 
representative samples were taken for radiometric analysis. Representative sections 
of small intestine were also taken for radiometric analysis. 
  
 
6 
Quantification of 14C radiolabel 
Skin samples from treatment sites were solubilised in up to 40 mL Soluene-
350™ (PerkinElmer), and the cotton swabs and surgical gauze used to remove 
residual SM or WoundStat™ from the treatment site were placed into isopropanol 
(20 mL). Vials were stored at ambient temperature for at least 14 days (with 
occasional vigorous shaking) to allow dissolution and extraction into the respective 
solvent. Radioactivity within the samples was quantified (disintegrations per minute) 
by liquid scintillation counting (Model 2810 Tri-Carb, PerkinElmer). Standard 
solutions containing known amounts of 14C-SM were prepared in triplicate for cotton 
swabs, surgical gauze, WoundStat™ and skin, using the same method as for the 
experimental samples. Aliquots (250 µL) of standards and experimental samples 
were diluted in a 5 mL Ultima Gold™ liquid scintillation cocktail (PerkinElmer) for 
analysis. Blood samples were colour-bleached to reduce quenching, using 
previously described methods (Moore, 1981). Briefly, triplicate aliquots of blood (0.4 
mL) were solubilised in 1 mL Soluene-350™ and isopropanol solution in a 1:2 ratio 
and incubated at 60°C for 2 h. Samples were cooled and incubated with hydrogen 
peroxide solution (0.5 mL; 30% v/v) for 30 min at ambient temperature. Blood 
samples were subsequently incubated at 60°C for 30 min. Triplicate organ samples 
(100 mg) were solubilised in Soluene-350™ (2 mL) with a 4 h incubation period at 
60°C. Both blood and organ samples were cooled and diluted in a 20 mL Ultima 
Gold™ liquid scintillation cocktail. 
Blood and organ samples for reference standards were obtained from non-
exposed animals. Standard solutions containing known amounts of 14C-SM were 
prepared in triplicate following the methods described above. To account for 
differences in weight/volume ratio among the organ samples the densities were 
determined using homogenised samples. Densities for organ samples were as 
follows; brain (0.87 g mL-1), heart (0.89 g mL-1), lungs (0.77 g mL-1), liver (0.98 g 
mL-1), spleen (0.96 g mL-1), pancreas (0.84 g mL-1), kidney (0.91 g mL-1) and small 
intestine (0.89 g mL-1). 
Both experimental samples and reference standards were analysed by liquid 
scintillation counting, using a 2 min count time, with the exception of the organ and 
blood samples, which used a 5 min count time. Pre-set quench settings were used 
for the Ultima Gold™ liquid scintillation cocktail. The quantity of radioactivity in each 
sample was converted to a measure of 14C-radiolabelled SM by comparison with the 
corresponding reference standards (measured simultaneously). Radiolabel (14C) 
elimination kinetics for the blood were calculated from linear regression analysis of a 
semi-logarithmic plot of blood concentration against time at steady state, where the 
decrease in concentration of 14C-SM with time was constant. Area under the curve 
(AUC), tmax and Cmax were calculated by non-compartmental analysis using 
GraphPad Prism version 6.01 for Windows (GraphPad Software). 
Histological analysis 
Full-thickness skin biopsies were collected from each treatment site post 
mortem and immediately fixed in 10% neutral buffered formalin. Fixed skin samples 
were processed through graded ethanol series and cleared prior to being infiltrated 
and embedded in paraffin wax. Wax-embedded blocks were sectioned at a nominal 
thickness of 5 µm and stained with haematoxylin and eosin. Stained skin sections 
were examined by a qualified histopathologist. Each section was subjectively scored 
for the occurrence and severity of several indicators, including keratinocyte necrosis, 
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eschar formation, sub-epidermal separation or vesication, blood vessel dilation, and 
inflammatory cell infiltrate. 
Statistical analysis 
For each parameter, the mean and standard deviation (SD) were calculated 
for each treatment site at each time point. Data from the untreated control skin sites 
and the damaged unexposed skin sites were pooled (separately) for the two groups 
of animals (SM control and WoundStat™ decontamination treatment groups) to 
facilitate graphical representation of the results. GraphPad Prism version 6.01 for 
Windows (GraphPad Software) was used for normality testing and statistical analysis 
of the data. Data were assessed for normal distribution using a D’Agostino and 
Pearson omnibus normality test and a Gaussian non-linear regression curve fit. 
Significance was predefined at an alpha-level of 0.05. 
One-way analysis of variance (ANOVA) with Bonferroni’s multiple 
comparisons post test was used for inter-group comparisons of normally distributed 
data. Student’s t-test was used to analyse differences between two normally 
distributed groups. For data that did not fit a Gaussian distribution, Kruskal–Wallis 
one-way ANOVA with Dunn’s post test was used to analyse multiple inter-group 
comparisons. Comparisons between two groups involving data that did not meet 
normal distribution criteria were analysed using a two-tailed Mann–Whitney U test. 
Results 
Gross clinical observations 
Exposure of damaged skin to SM resulted in skin blanching at the treatment 
site within 60 min for all animals in the SM control group. All animals in this group 
also developed an ulcerated area or skin erosion directly below the SM droplet within 
6 hours, as evidenced by a pale area of skin with a “peau d’orange” appearance. In 
the WoundStat™ decontamination group, observable skin blanching was reduced by 
two thirds (2 out of 6 animals) and no ulcerated area developed in any of the 6 
animals. 
Treatment with WoundStat™ did not significantly change the frequency (n=4/6 
animals) or time to the appearance of erythema, with the median time to observable 
erythema being 120 min for both treated and untreated sites. Decontamination with 
WoundStat™ both reduced the frequency of oedema at the exposure site (n=2/6 
animals in WoundStat™ decontamination group), and prolonged the latency period 
between the SM challenge and the appearance of oedema compared to the SM 
control group (180 min vs. 100 min, respectively). 
Overall there were no remarkable visual changes seen over the 6-hour study 
period for the control (undamaged skin) site and damaged skin site for either group 
of animals. Additionally, application of WoundStat™ did not appear to adversely 
affect damaged skin, as there was no notable difference in appearance between the 
treated and untreated sites that had not been exposed to SM. 
Microscopic skin structure changes 
Histological examination confirmed that dermatoming achieved complete 
removal of the SC and epidermis (Figure 1). The remaining intact epithelium (at the 
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edge of the treatment site) was histologically normal, as were the hair follicles and 
other adnexal structures. All control (undamaged) skin slides appeared normal for 
both treatment groups. 
There were no significant microscopic differences between the damaged and 
SM skin sites for animals in the SM control group (Table 1). Additionally, there were 
no significant microscopic differences between SM-exposed sites with and without 
decontamination using WoundStat™ (Table 1). Both groups showed mild, 
perivascular, polymorphonuclear neutrophil (PMN) infiltrate in the dermis (Figure 1), 
as well as increased PMNs within the capillary lumen (Table 1). These findings were 
consistent with secondary tissue damage caused by the dermatome, which was 
observed at the damaged unexposed skin sites in both SM control and WoundStat™ 
decontamination groups. 
Biophysical measurements 
Cutaneous blood flow (laser Doppler imaging) 
Overall, blood flow increased at the treatment sites during the 6 h study period 
(Figures 2 and 3). However, exposure to SM significantly reduced skin blood flow 
compared to unexposed damaged skin sites from 180 min post-exposure until the 
study end at 6 h post exposure (Figure 2), with a distinct area of low flux observed at 
the site of the SM application (Figure 3). Decontamination with WoundStat™ 
prevented this significant decrease in blood flow at all time points except 120 min 
post-exposure (Figure 2). Furthermore, the distinct area of low flux observed at the 
SM treatment site following SM exposure was not observed at sites treated with 
WoundStat™ (Figure 3). 
Skin barrier integrity (transepidermal water loss) 
Overall, removal of the SC and epidermis, regardless of any additional 
intervention (WoundStat™ and/or SM), resulted in a statistically significant increase 
in TEWL compared to control (undamaged) skin sites. No statistically significant 
difference was observed between WoundStat™ treated skin with or without prior 
SM-exposure (Figure 4). However, sites treated with WoundStat™ had significantly 
higher TEWL values compared to untreated damaged skin sites and SM-exposed 
sites at 120 min post-exposure (Figure 4). Additionally, SM sites treated with 
WoundStat™ showed significantly greater TEWL values compared to SM treatment 
sites at 60, 180 and 240 min post exposure (Figure 4).  
Skin colour (skin reflectance spectroscopy) 
Removal of the upper skin layers significantly decreased skin brightness (L* 
CIELAB parameter) and significantly increased skin redness (a* CIELAB parameter) 
and skin hue or yellowness (b* CIELAB parameter) compared to undamaged skin 
sites (P<0.01; data not shown). However, treatment with WoundStat™ was not 
associated with a significant difference in any of the skin colour parameters 
measured at SM-exposed sites. Exposure to SM without decontamination using 
WoundStat™ resulted in a distinct trough at ~420 nm in the skin reflectance spectra 
at 6 h post-exposure, when data were expressed as a percentage change from 
baseline values; this was not observed at any other skin sites (Figure 5). Conversely, 
skin reflectance between ~450–600 nm was greater at SM-exposed sites treated 
with WoundStat™ than at all other sites. 
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Skin surface temperature (infrared thermography) 
Damage to the skin (removal of the SC and epidermis) resulted in a significant 
decrease in skin surface temperature (data not shown). However, no significant 
difference in skin surface temperature was observed between any of the damaged 
skin treatment sites (data not shown). 
Toxicokinetics 
Blood concentrations of 14C-SM peaked at 120 min post-challenge for both 
SM control and WoundStat™ decontamination groups (Figure 6). However, 
WoundStat™ treatment post-exposure significantly reduced the amount of 14C-SM 
measured in the blood at all time points (42–50% reduction; Figure 6). Elimination 
kinetics parameters, including peak concentration, slope and elimination constant, 
were derived from a semi-logarithmic plot of the 14C-SM blood concentrations, as 
shown in Figure 6. These parameters were significantly decreased, whilst the 
apparent volume of distribution was significantly increased for animals in the 
WoundStat™ decontamination group compared to those in the SM control group 
(P<0.01, Figure 6). However, there was no significant difference in either the 
apparent half-life of 14C-SM or the SM dose (calculated from the apparent volume of 
distribution and Cmax) between the two groups (Figure 6). 
Distribution of 14C-sulphur mustard 
Overall, 6.3 ± 1.6% of the applied dose of 14C-SM was recovered from 
samples taken from animals in the SM control group, including exposure site skin, 
skin surface swabs, organs and blood. The skin surface swabs and exposure site 
skin accounted for the largest proportion of 14C-SM recovered. Use of WoundStat™ 
as a decontaminant significantly reduced the amount of 14C-SM recovered from the 
skin (85 ± 16 µg vs. 279 ± 24 µg) and skin surface swabs (4 ± 1 µg vs. 440 ± 82 µg) 
compared to animals in the SM control group (Figure 7). The 14C-SM recovered from 
WoundStat™ accounted for the majority (99 ± 8%) of the recovered 14C-SM dose for 
animals in the WoundStat™ decontamination group (Figure 7). 
Despite the significant decrease in the amount of 14C-SM absorbed following 
WoundStat™ decontamination compared to the SM control group, the amount of 
14C-SM in the organ samples was very similar in both groups (Figure 8). In both 
groups, when the data were expressed as ng of 14C-SM per g of organ weight, the 
predominant distribution of 14C-SM in the organs was the same: primarily the kidney, 
followed by the liver and small intestine (Figure 8). However, there were significant 
differences between the SM control and WoundStat™ decontamination groups in the 
amount of 14C-SM recovered from the liver samples (Figure 8). 
Discussion 
This study has demonstrated that removal of the skin barrier layer (SC and 
epidermis) resulted in the rapid onset of advanced signs of SM toxicity, including 
ulceration, eschar formation and reduced dermal blood flow, with a shorter latency 
period compared to that of undamaged skin exposed to the same amount of SM 
(Larner, unpublished observations). The latency period between exposure and 
advanced signs of SM toxicity was also shorter than that reported in studies 
conducted by Reid and colleagues, in which both the amount of SM applied to the 
skin (400 μL) and the exposure duration (2 h) were greater than those used in this 
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study (Reid et al., 2000). The rapid appearance of these advanced signs of toxicity 
correlated with an increased rate of absorption in vivo and these data are in 
agreement with in vitro percutaneous penetration studies (Lydon et al., 2017). This 
suggests that the latency period between SM exposure and the appearance of 
symptoms in undamaged skin could be in part due to delayed absorption and not, as 
previously hypothesised, exclusively by cellular processes such as DNA damage or 
inflammatory-mediated responses (Arroyo et al., 2000; Papirmeister et al., 1985). 
The rapid onset of symptoms of severe toxicity associated with the exposure of 
barrier-compromised skin to SM may potentially reduce the window of opportunity for 
successful therapeutic interventions. However, application of WoundStat™ to the 
exposure site prevented or delayed signs of toxicity, including ulceration; thus, the 
use of WoundStat™ as a decontaminant may reduce lesion severity and increase 
the time interval during which additional therapeutic interventions may be effective. 
To our knowledge, this study is the first to examine the toxicokinetics and 
distribution of 14C-SM when applied percutaneously to superficially damaged skin. 
Absorption of 14C-SM into the circulation was rapid, and the toxicokinetics of 14C-SM 
in the blood followed a first-order non-compartmental model with an apparent half-life 
of 460 ± 62 min. SM has been found to form a skin reservoir within the SC in vitro 
(Hattersley et al., 2008), although it is not clear whether any reservoir of active SM 
forms in the dermis if the SC is removed. However, SM rapidly spreads across the 
surface of human skin in vitro (Chilcott et al., 2000) and so could form a reservoir in 
the SC in the undamaged skin surrounding the area of damaged skin. Total recovery 
of 14C-SM from the skin, skin surface swabs, blood and internal organ samples in the 
SM control group was congruent with the percentage dose penetration in an ex vivo 
isolated perfused porcine skin flap model at a comparable time-point (Riviere et al., 
1995). For animals in the SM control group, the largest proportion of 14C-SM was 
recovered from the skin surface swabs and the skin at the exposure site. Once 
absorbed, the majority of the 14C resided within either the skin or blood, which is in 
agreement with previous studies (Hambrook et al., 1992). Application of 
WoundStat™ significantly reduced the amount of 14C-SM recovered from both skin 
surface swabs and skin at the exposure site compared to the SM control group 
(P<0.001), with the majority of the 14C-SM dose being sequestered in the retained 
WoundStat™. 
The distribution of radioactivity within internal organs is in agreement with 
studies in the literature (Black et al., 1992; Davison et al., 1961; Hambrook et al., 
1992; Maisonneuve et al., 1993). Decontamination with WoundStat™ significantly 
reduced the amount of 14C-SM detected in the liver, presumably by inhibiting the 
dermal absorption of SM. However, the use of liquid scintillation counting to quantify 
14C-SM does not allow for speciation of the 14C-radiolabel isotope. Metabolite 
identification was not the primary focus of this work, but it has previously been 
shown that SM is conjugated or hydrolysed in vivo (Black et al., 1992; Capacio et al., 
2004). Thus, the smaller amount of 14C isotope measured in the liver could be 
attributed to changes in the concentration of hydrolysis or conjugation products as a 
result of an altered SM metabolism (Black et al., 1992; Black and Read, 1995), 
rather than just a reduction in systemic absorption. Speciation of radiolabelled 
compounds using previously characterised techniques (Noort et al., 2008, 1999) 
would enable the identification of the SM parent molecule or metabolites and 
conjugates within samples. 
The biophysical methods used in this study enable a non-invasive and 
quantitative assessment of SM injuries, offering considerable ethical refinement and 
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reducing the number of animals required. These methods permit sequential 
measurements under terminal anaesthesia over a shorter time frame, whereas SM 
injuries would previously have been assessed visually or by histopathology, typically 
14 to 21 days post-exposure. 
This study has built on previous work in demonstrating the usefulness of laser 
Doppler imaging (LDI) in measuring SM lesion progression (Braue et al., 2007; 
Brown et al., 1998; Chilcott et al., 2000). All animals in the SM control group rapidly 
developed (within 60 min of exposure) an area of blanched skin surrounding the SM 
droplet, which correlated with a foci of reduced maximal blood flow, as measured by 
LDI. Histopathological analysis revealed capillary dilation and congestion of 
subepidermal capillaries with perivascular inflammatory cell infiltrate, consistent with 
other published studies that also reported significantly reduced skin blood flow at the 
lesion site (Brown et al., 1998; Brown and Rice, 1997). Whilst a transient decrease in 
perfusion units was seen following WoundStat™ decontamination of SM-exposed 
skin (compared to WoundStat™-treated unexposed skin), sustained foci of reduced 
blood flow were not observed. Moreover, the frequency of visual blanching at the 
exposure site also decreased following decontamination with WoundStat™.  
In contrast, this study has highlighted that some other commonly used 
biophysical measurements (skin reflectance spectroscopy, infrared thermography 
and TEWL water loss) may have limited value when investigating the response of 
damaged skin to SM, as initial pathological changes could be masked by the 
mechanical damage caused by dermatoming. Removal of the SC and epidermis 
resulted in statistically significant increases in both skin redness (a*) and hue (b*). 
The increase in these two parameters can be attributed to punctate haemorrhage 
and inflammation (increased a* or skin redness) and sero-cellular crusting or eschar 
formation (increased b* or skin yellowness) following the removal of the upper skin 
layers. In contrast with previous studies, SM did not have a significant effect on skin 
colour in terms of CIELAB L*a*b* parameters compared to the appropriate control 
site (Chilcott et al., 2000). Similarly, there was no significant difference in the colour 
parameters measured (L*, a* and b*) between the SM control and the WoundStat™ 
decontamination treatment groups. This was unexpected, as erythema at the 
exposure site was visible in half the animals at 2 hours post challenge. However, 
removal of the upper skin layers resulted in the unexposed skin becoming 
erythematous. Therefore, although a qualitative difference in skin redness was 
observed between the SM-exposed and unexposed skin it was not deemed 
statistically significant in terms of the a* value. 
Despite the lack of SM-dependent effects on CIELAB colour values there 
were overt changes in the skin reflectance spectra between the treatment groups. 
Most notable was the increase in skin absorbance at ~420 nm at 6 h post-exposure 
for the SM-only site. Such changes in the absorption spectra may be attributed to an 
increase in bilirubin levels (Anderson and Parrish, 1981) which has previously been 
reported following SM exposure in humans (Pourfarzam et al., 2009). Increased 
bilirubin could be a direct result of toxic effects of SM on the liver. The hepatic 
metabolism of SM has been reported in the literature (Black and Read, 1995; Halme 
et al., 2015; Jafari, 2007) and radiometric data from this study provide further 
evidence that 14C-SM or radiolabelled metabolites of SM are associated with the 
liver. Furthermore, decontamination with WoundStat™ significantly decreased the 
amount of radiolabelled 14C detected in the liver, which is consistent with the 
absence of increased skin absorption at ~420 nm in this group. Alternatively, 
bilirubin, like glutathione (GSH), has been shown to have an antioxidant and 
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cytoprotective role (Sedlak et al., 2009). Whilst GSH primarily protects hydrophilic 
proteins, bilirubin is lipophilic and prevents oxidative damage to lipids and lipophilic 
proteins (Sedlak et al., 2009). GSH has a well-established role in cellular defence 
and depletion of GSH levels is associated with SM toxicity (Jafari, 2007), whereas 
administration of exogenous GSH has been shown to be protective in vitro and in 
animal models (Tewari-Singh et al., 2011). Thus, bilirubin may act as an antioxidant 
in lipophilic environments such as the skin and so act as a defence mechanism 
against SM-associated lipid peroxidation.  
Unsurprisingly, removal of the skin barrier (loss of SC and epidermis) with a 
dermatome resulted in significantly increased TEWL rates compared to undamaged 
control values. However, over the 6-hour study period no significant differences were 
observed for damaged skin sites with and without SM-exposure in the SM control 
group. Presumably this is because the key factor associated with increased 
evaporative water loss in this model is the complete removal of the barrier layer. 
Thus, any additional changes associated with SM exposure were not evident up to 6 
h post-exposure, which is consistent with findings from previous studies using 
undamaged skin porcine models (Chilcott et al., 2000). Moreover, the application of 
WoundStat™ to damaged skin resulted in significantly greater TEWL values 
compared to other damaged skin sites (±SM exposure). The phenomenon of 
increased TEWL in response to the application of semi-occlusive dressings has been 
previously reported (Schunck et al., 2005). Therefore, whilst WoundStat™ is in situ it 
may act as a barrier to TEWL and so prevent the normal increased TEWL feedback 
mechanism associated with complete barrier loss. This may conceivably prevent the 
stimulation of parakeratosis and other related barrier mechanisms, which are 
normally rapidly activated in open wounds to prevent the ingress of harmful 
substances or bacteria (Schunck et al., 2005). 
Exposure of damaged skin to SM did not result in any significant microscopic 
differences compared to either unexposed damaged skin or skin at WoundStat™ 
decontaminated sites. This was unexpected, given the significant differences in both 
blood flow and the amount of 14C-SM retained within the skin at WoundStat™ 
decontaminated sites compared to sites not receiving decontamination. However, 
the presence of a few definite structural alterations at 6 hours post exposure is in 
agreement with previous SM studies using undamaged skin study (Brown and Rice, 
1997; Greenberg et al., 2006), although these studies observed SM-associated focal 
vacuolation and pyknotic nuclei in basal keratinocytes, which were not observed in 
the present study. It is likely that the removal of the epidermis and the associated 
acute inflammatory response resulting from the initial tissue damage may mask any 
additional histopathological changes caused by SM at this early time point. With that 
in mind, one concern with using skin sites from the same animal as a control was the 
induction of a systemic inflammatory response to SM that could affect the 
surrounding dorsal skin. However, no significant microscopic changes in the gross 
skin structure at undamaged control skin sites were observed in either the SM 
control or WoundStat™ decontamination groups. 
Conclusions 
Direct application of SM to superficial wounds results in the rapid appearance 
of advanced signs of toxicity, such as ulceration and reduced blood flow, and may 
increase the urgency for the effective decontamination of SM-contaminated wounds. 
In addition, there is evidence to suggest that the latent period between SM exposure 
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and the appearance of symptoms may be attributed in part to delayed absorption 
and not exclusively to cellular processes, as previously described. Moreover, this 
study has built upon the previous evidence base describing the usefulness of LDI for 
monitoring SM injuries and highlights the limitations of commonly used biophysical 
measurements (SRS, infrared thermography and TEWL) when monitoring SM 
injuries on damaged skin. This study also demonstrates that the timely application of 
WoundStat™ can prevent advanced signs of SM dermal toxicity, namely ulceration, 
improve blood flow at the exposure site, and significantly reduce the amount of 14C-
SM recovered from the blood, skin and liver. 
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Figure legends 
 
Figure 1. Structural changes following exposure of superficially damaged porcine 
skin to 14C-SM and decontamination with WoundStat™. Representative histological 
sections prepared from SM-exposed, WoundStat™-decontaminated damaged skin 6 
h post-exposure. Eschar formation (E) and neutrophilic cell infiltrate (arrows) are 
shown. Sections were stained with haematoxylin and eosin and viewed by bright-
field microscopy. One representative section from the 6 pigs in the treatment group 
is shown (original magnification ×20). 
 
Figure 2. Maximum blood perfusion at skin treatment site for the SM control (SM) 
and WoundStat™ decontamination (WS + SM) treatment groups. Damaged 
unexposed sites (Damaged) provided a negative control. All values are expressed as 
mean ± SEM (n=6). Statistically significant differences were found when both SM 
control (SM) and WoundStat™ decontamination (WS + SM) treatment groups were 
compared to the damaged group. *, *** and **** represent P-values of <0.05, <0.001 
and <0.0001, respectively.  
 
Figure 3. Representative skin perfusion images (laser Doppler imaging) for the SM 
control (SM) and WoundStat™ decontamination (WS + SM) treatment groups. Laser 
Doppler images of skin with and without SM exposure (but no WoundStat™ 
decontamination are shaded in grey One representative image from 6 pigs/treatment 
group is shown. 
 
Figure 4. Transepidermal water loss (TEWL) for skin treatment sites in the SM 
control (SM) and WoundStat™ decontamination (WS + SM) treatment groups. Flux 
values (g cm-2 h-1) were expressed as a percentage of undamaged control sites for 
each time point. Damaged unexposed (damaged) and damaged WoundStat™-
treated (WS) sites served as respective controls All values are expressed as mean ± 
SD (n=6). Statistically significant differences compared to SM (asterisk) or damaged 
(dollar sign) are indicated where * or $, ** or $$, ***or $$$ and **** or $$$$ represent 
P-values of <0.05, <0.01, <0.001 or <0.0001, respectively. 
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Figure 5. Skin reflectance spectra at 6 hours post-exposure for the SM control (SM) 
and WoundStat™ decontamination (WS + SM) treatment groups. Data are 
expressed as percentage changes from baseline values taken immediately prior to 
dosing. Damaged unexposed (damaged) and damaged WoundStat™ treated (WS) 
sites served as controls. All values are expressed as mean ± SD (n=6). 
 
Figure 6. Measured blood concentrations of 14C-SM for SM control (SM) and 
WoundStat™ decontamination (WS + SM) treatment groups. Individual values are 
expressed as mean ± SD (n=6).  
 
Figure 7. Recovery of 14C-SM from the samples (WoundStat™, skin surface swabs 
and skin) expressed as quantity of 14C-SM (µg) recovered in the SM control (SM) 
and WoundStat™ decontamination (WS + SM) treatment groups. All values are 
mean ± SD (n=6). Data are log transformed to enable comparison. Significant 
differences between the treatment groups (WS + SM vs. SM) are shown, where *** 
represents a P-value of <0.001.  
 
Figure 8. Recovery of 14C-SM from internal organs expressed as ng (SM) per g 
(organ weight) for the SM control (SM) and WoundStat™ decontamination (WS + 
SM) treatment groups. All values are expressed as mean ± SD (n=6). Statistically 
significant differences between the treatment groups (WS + SM vs. SM) are shown, 
where * represents a P-value of <0.05. 
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Table 1. Occurrence and severity of histopathological changes in skin following 
exposure of superficially damaged porcine skin to 14C-SM and/or decontamination 
with WoundStat™. Representative histological sections prepared from skin taken 6 h 
post-exposure for unexposed undamaged skin (control), unexposed damaged skin 
(damaged), unexposed WoundStat™ decontaminated (WS), SM-exposed (SM), and 
SM-exposed WoundStat™ decontaminated (WS + SM) treatment sites. Lesions 
were scored histopathologically, on a scale where marked > moderate > mild > 
minimal > normal indicate the severity of the lesion. Numbers in brackets indicate 
the numbers of animals in each severity group. 
 
Lesion 
Treatment Group 
Control 
(n=12) 
Damaged 
(n=12) 
WS 
(n=6) 
SM 
(n=6) 
WS + SM 
(n=6) 
Surface and follicular 
keratinocyte necrosis (n) Normal (12) Normal (12) Normal (6) Normal (6) Normal (6) 
Subepidermal separation Normal (12) Normal (12) Normal (6) Normal (6) Normal (6) 
Blood vessel dilation Normal (12) Normal (4) Minimal (8) 
Normal (5) 
Minimal (1) 
Normal (2) 
Minimal (4) Normal (6) 
Perivascular to diffuse, 
neutrophilic cell infiltrate Normal (12) Mild (12) Mild (6) Mild (6) Mild (6) 
Eschar formation Normal (12) Mild (2) Moderate (10) 
Mild (1) 
Moderate (5) 
Minimal (2) 
Mild (4) 
Mild (2) 
Moderate (3) 
Marked (1) 
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Table 2. Calculated elimination kinetics of 14C-SM for SM control (SM) and 
WoundStat™ decontamination (WS + SM) treatment groups. Individual values are 
expressed as mean ± SD (n=6). Elimination kinetics are derived from linear 
regression analysis of a semi-logarithmic plot of whole blood concentration against 
time. The equations used were described by Shen (2008). Significant differences 
between the SM and WS + SM treatment groups are shown, where * and ** 
represent P-values of <0.05 and <0.01, respectively 
 
 SM WS + SM 
t½ (min) 425 ± 60 468 ± 121 
Cmax (ng.mL-1) 60.8 ± 64 **33.0 ± 7.4 
tmax (min) 120 ± 0 90 ± 33 
AUC  
(ng.min.mL-1) 
17240 ± 1828 **9407 ± 1922 
Slope (pg.mL-1.min-1) -64.7 ± 9.0 *-34.4 ± 13.3 
Kel (pg.mL-1.min-1) 149 ± 21 *79.1 ± 30.7 
Vd/F (L) 190 ± 22 ***371 ± 83 
D (mg) 11.5 ± 0.5 11.7 ± 0.3 
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